Market Cap
$402.1M
RLMD
RELMADA THERAPEUTICS, INC.
$3.60 ▼ -1.64%
Prev close $3.66Market cap$402.1M
12-mo target$10.75 (+198.6%)
Insider Buying Cluster (2 insiders)15 New Institutional Positions8 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on RLMD right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$380.1M
Inst. Activity
15 buys / 8 sells
Insider Activity
$1.7M buy / $0.00 sell
Insider Net $
$1.7M
SEC Reports
5
Press Releases
3
Price chart 30d -17.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 11, 2026 SEC
RLMD CEO Sergio Traversa and CFO Maged Shenouda collectively purchased $1.67M of stock in open-market transactions over
CLUSTER — Impact 6/10
Sep 11, 2026 short_volume
Short Volume: RLMD — 59.9% short (0.6M / 1.0M)
Short: 615,350 | Exempt: 1,784 | TRF Vol: 1,027,853 | Short Ratio: 59.9% | Off-exchange volume (dark
Sep 10, 2026 Insider
Shenouda Maged bought 79,800 shares
Chief Financial Officer @ $4.25 ($339.1K)
Sep 10, 2026 Insider
TRAVERSA SERGIO bought 100,000 shares
Chief Executive Officer @ $4.10 ($410.0K)
Sep 9, 2026 Insider
Shenouda Maged bought 120,200 shares
Chief Financial Officer @ $4.20 ($504.8K)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
7,426,780 shares ($51.4M)
Jun 30, 2026 Inst.
May 13, 2026 SEC VANGUARD CAPITAL MANAGEMENT LLC — ADD
4,460,210 shares ($30.9M)
Relmada Therapeutics filed an automatic shelf registration statement (S-3ASR) on May 13, 2026, registering an indetermin
S-3ASR — Impact 6/10
Analyst ratings buy % +3.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 18, 2026 | HC Wainwright & Co. | INITIATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Aug 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% |
Price targets
Where 4 covering analysts think RLMD trades over the next 12 months.
$10.75 +198.6% upside Strong Buy
Current$3.60 Low$9.00 Median$11.00 High$12.00 4 analysts
$9.00$12.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 3 neutral · avg impact 4.4/10.Plus 3 press releases.
BULLISHCLUSTER6/10
RLMD CEO Sergio Traversa and CFO Maged Shenouda collectively purchased $1.67M of stock in open-marke
Sep 11, 2026
BEARISHS-3ASR6/10
Relmada Therapeutics filed an automatic shelf registration statement (S-3ASR) on May 13, 2026, regis
May 13, 2026
NEUTRAL8-K4/10
Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage
May 12, 2026
NEUTRALDEFA14A3/10
Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key pro
Apr 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 11, 2026
short_volume
Short Volume: RLMD — 59.9% short (0.6M / 1.0M)
Short: 615,350 | Exempt: 1,784 | TRF Vol: 1,027,853 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: RLMD — 83.3% short (1.3M / 1.6M)
Short: 1,339,179 | Exempt: 0 | TRF Vol: 1,607,055 | Short Ratio: 83.3% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: RLMD — 79.5% short (0.4M / 0.6M)
Short: 441,499 | Exempt: 425 | TRF Vol: 555,597 | Short Ratio: 79.5% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
short_volume
Short Volume: RLMD — 61.1% short (0.5M / 0.8M)
Short: 460,886 | Exempt: 777 | TRF Vol: 754,109 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
Sep 1, 2026
other
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotech
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.14 | $-0.16–$-0.14 | 51.7% | +32.2% | 1↑ 0↓ | $0.0B | 4 |
| Next Q | $-0.16 | $-0.17–$-0.14 | 45.7% | +32.1% | 1↑ 0↓ | $0.0B | 4 |
| Current FY | $-0.41 | $-0.41–$-0.41 | 62.8% | -13.9% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $-0.41 | $-0.41–$-0.41 | 0.0% | +10.9% | 0↑ 1↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.145 | — |
| 7d ago | $-0.146 | +0.001 |
| 30d ago | $-0.214 | +0.069 |
| 60d ago | $-0.214 | +0.069 |
| 90d ago | $-0.205 | +0.060 |
Institutional ownership
Which big funds own RLMD (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $380.1M total value (54,921,438 shares) as of 2026-Q2. Top holders: Jupiter, BlackRock,, ADAGE. Net buying activity: 15 institutions added/increased vs 8 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Jupiter Topco LLC | 11,164,803 | $77.3M | 20.3% | — |
| BlackRock, Inc. | 7,426,780 | $51.4M | 13.5% | DOUBLED +475.9% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,763,158 | $33.0M | 8.7% | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,460,210 | $30.9M | 8.1% | ADD +45.0% |
| STATE STREET CORP | 2,517,550 | $17.4M | 4.6% | DOUBLED +605.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,492,573 | $17.3M | 4.5% | DOUBLED +193.7% |
| MILLENNIUM MANAGEMENT LLC | 2,361,827 | $16.3M | 4.3% | TRIM -39.6% |
| MARSHALL WACE, LLP | 2,246,839 | $15.5M | 4.1% | TRIM -49.9% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,132,053 | $14.8M | 3.9% | DOUBLED +154.1% |
| AMERIPRISE FINANCIAL INC | 1,937,972 | $13.4M | 3.5% | DOUBLED +263.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 1,289,550 | 7,426,780 | +475.9% | $51.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 3,076,570 | 4,460,210 | +45.0% | $30.9M |
| STATE STREET CORP | DOUBLED | 357,040 | 2,517,550 | +605.1% | $17.4M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 848,683 | 2,492,573 | +193.7% | $17.3M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 3,907,265 | 2,361,827 | -39.6% | $16.3M |
| MARSHALL WACE, LLP | TRIM | 4,481,606 | 2,246,839 | -49.9% | $15.5M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 533,258 | 1,937,972 | +263.4% | $13.4M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 252,457 | 1,520,688 | +502.4% | $10.5M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 125,941 | 812,059 | +544.8% | $5.6M |
| NORTHERN TRUST CORP | DOUBLED | 157,734 | 786,257 | +398.5% | $5.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
2 insiders, 4 transactions. Net $1.7M — $1.7M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Shenouda Maged | Chief Financial Officer | BUY | 79,800 | $4.25 | $339.1K |
| Sep 10, 2026 | TRAVERSA SERGIO | Chief Executive Officer | BUY | 100,000 | $4.10 | $410.0K |
| Sep 9, 2026 | Shenouda Maged | Chief Financial Officer | BUY | 120,200 | $4.20 | $504.8K |
| Sep 9, 2026 | TRAVERSA SERGIO | Chief Executive Officer | BUY | 100,000 | $4.18 | $418.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RLMD.
Shares short
14,463,677
Settlement Sep 15, 2026
Change vs prior
+6.3%
Semi-monthly cycle
Days to cover
9.3
At avg daily volume
Of shares outstanding
≈13.6%
Estimate — not % of float
All RLMD filing & press-release reports (8)
- CLUSTER reportSep 11, 2026
- S-3ASR reportMay 13, 2026
- 8-K reportMay 12, 2026
- DEFA14A reportApr 17, 2026
- S-3 reportApr 3, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 12, 2026
- PRESS-RELEASE reportMar 9, 2026